Johnson & Johnson JNJ
NYSE JNJ
$270.24 +2.87 (+1.07%)
At close: Aug 21, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026)

Johnson & Johnson (JNJ) posted Total Non-Current Liabilities of $106.0 billion for Q2 2026, down 3.21% sequentially from $109.5 billion in Q1 2026, and down 6.83% YoY from $113.8 billion in Q2 2025.

Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends

Johnson & Johnson has reported Total Non-Current Liabilities for 18 years, with the latest figure at $106.0 billion in Q2 2026.

  • Quarterly Total Non-Current Liabilities fell 6.83% year-over-year to $106.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $106.0 billion (down 6.83% YoY) and the FY2025 annual result came in at $107.8 billion, changed 0.37% from the prior year.
  • Total Non-Current Liabilities eased to $106.0 billion in Q2 2026 per JNJ's latest filing, from $109.5 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $124.0 billion in Q2 2023 and troughed at $93.7 billion in Q4 2023.
  • A 5-year average of $106.8 billion and a median of $107.4 billion in 2024 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities gained 20.16% in 2023, then dropped 18.66% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $100.0 billion in 2022, then slipped by 2.31% to $97.7 billion in 2023, then rose by 9.93% to $107.4 billion in 2024, then advanced by 0.37% to $107.8 billion in 2025, then fell by 1.68% to $106.0 billion in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $106.0 billion, $109.5 billion, and $107.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 105.99 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 100.51 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 122.23 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 33.91 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 92.80 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 47.87 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 100.86 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -30.89 Bn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn 32.04 Bn

Historic Data

Download Data
DateValue
Jun 28, 2026 105.99 Bn
Mar 29, 2026 109.50 Bn
Dec 28, 2025 107.80 Bn
Sep 28, 2025 103.61 Bn
Jun 29, 2025 113.76 Bn
Mar 30, 2025 114.33 Bn
Dec 29, 2024 107.40 Bn
Sep 29, 2024 106.91 Bn
Jun 30, 2024 108.30 Bn
Mar 31, 2024 100.83 Bn
Dec 31, 2023 97.69 Bn
Oct 1, 2023 93.66 Bn
Jul 2, 2023 114.14 Bn
Apr 2, 2023 123.96 Bn
Jan 1, 2023 109.45 Bn
Oct 2, 2022 100.00 Bn
Jul 3, 2022 100.83 Bn
Apr 3, 2022 103.16 Bn
Jan 2, 2022 107.46 Bn
Oct 3, 2021 108.34 Bn